5-Fluoro-3-iodo-1H-pyrazolo[3,4-b]pyridine

Catalog No. :
ACQBKH875
CAS No. :
1350653-23-4
Molecular Formula :
C6H3FIN3
Molecular Weight :
263.01

IUPAC Name:5-fluoro-3-iodo-1H-pyrazolo[3,4-b]pyridine

5-Fluoro-3-iodo-1H-pyrazolo[3,4-b]pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g98%$89.00Login to see priceIn stockIn stock
5g98%$358.00Login to see priceIn stockIn stock
25g98%$1676.00Login to see priceIn stockInquiry
100g98%$6097.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-Fluoro-3-iodo-1H-pyrazolo[3,4-b]pyridine
IUPAC Name5-fluoro-3-iodo-1H-pyrazolo[3,4-b]pyridine
MDL No.MFCD20923264
Molecular FormulaC6H3FIN3
Molecular Weight263.01
SMILESIC1=NNC2=NC=C(F)C=C21
InChI KeyHSJHOTUQSLQXLL-UHFFFAOYSA-N
Synonym5-FLUORO-3-IODO-1H-PYRAZOLO[3,4-B]PYRIDINE | 1350653-23-4 | 5-fluoro-3-iodo-2H-pyrazolo[3,4-b]pyridine | MFCD20923264 | 1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodo- | C6H3FIN3 | SCHEMBL174737 | DTXSID60735442 | HSJHOTUQSLQXLL-UHFFFAOYSA-N | PB21538 | 5-Fluoro-3-iodopyrazolo[
CAS No.1350653-23-4
PubChem CID66614055

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACQBKH875 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACSLCT870 route compound structure diagram
    ACSLCT8701034667-22-5 In Stock
  2. Then
  3. ACQBKH875 route product structure diagram
    ACQBKH8751350653-23-4 In Stock
Inquiry

2. ACQBKH875 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACSLCT870 route compound structure diagram
    ACSLCT8701034667-22-5 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACQBKH875 route product structure diagram
    ACQBKH8751350653-23-4 In Stock
Inquiry

Comments (0)